Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

On Track To Approval, Alkermes Hopes ALKS-5461 Can Change Future Of Depression Therapy

magnetic resonance image (MRI) of the brain human

Related Content

Opioids And Psychic Pain: Alkermes Uses High-Profile Stage To Highlight Depression Drug

Oct 10 2017

If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There

Oct 24 2016

FDA Reversal Puts Alkermes Depression Drug Back On Track For January Approval

Apr 17 2018

J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression

May 07 2018

Related Companies

Alkermes plc

Johnson & Johnson

Sage Therapeutics, Inc.

Additional Topics

Clinical Trials Commercial Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window